Stocks · News reference
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.76) per share. This is a 93.47 percent increase over losses of $(11.64) per share from the same period last year.
Read original at benzingaFiled: 2026-08-14 AccNo: 0001493152-26-038385 Size: 260 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarEnveric Biosciences reports new preclinical data supporting the non-hallucinogenic profile of its lead psychiatric drug candidate, EB-003.
Read original at benzingaPreclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega
Read original at benzingaGuggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $34 to $40.
Read original at benzingaCantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $35 to $40.
Read original at benzinga